Skip to content
Tuesday 25 August 2026London --:--Frankfurt --:--Zurich --:--
NewslettersSearchEN · DE · FR
MorningWire

European business, markets and politics

FTSE 100
10,863.27
+0.08%
DAX
26,290.92
+0.71%
CAC 40
8,478.31
+0.30%
STOXX 50
6,474.62
+0.41%
  • Europe
  • Markets
  • Business
  • Economy
  • Regulation
  • Politics
  • Opinion
More
GermanyFranceEU InstitutionsCompetitionPublic AffairsBankingTechnologyEnergy
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Economy
  • Regulation
  • Politics
  • Opinion
  • DE
Monday 09 September 2019 5:20 pm  |  Updated:  Monday 09 September 2019 6:24 pm

Blazing success: British cannabis company raises £7.8m in funding round

By: Anna Menin

Add as a preferred source on Google

A leading British cannabis company has raised £7.8m in a Series A funding round as it prepares to launch an “aggressive strategy” to dominate the budding industry across Europe.

Cannaray, which manufactures medical cannabis and consumer cannabidiol (CBD) products, also announced that it had bought Therismos – a company with licences to import, handle and distribute controlled drugs in the UK and across the EU.

Read more: World’s largest cannabis company Canopy Growth snaps up beauty brand This Works for £43m

The company has also partnered with Newey, the largest horticulture firm in the UK and an investor in Cannaray, to develop growing facilities and a pharmaceutical research base to “explore new cannabis-based medical formulations”. It is also applying for a cannabis cultivation licence – only two of which have ever been granted before.

The global medical cannabis market is set to be worth over £60bn by 2026, while the CBD consumer sector is predicted to hit £20bn by 2024.

Medical cannabis has been a hotly-debated topic in the UK recently, with the head of the world’s largest medical cannabis company, Aurora Cannabis, urging the government to allow GPs to prescribe the drug in June.

It has been legal for the NHS to prescribe cannabis since November last year, but campaigners have argued that under current rules the drug is almost impossible to access.

Cannaray said it is planning to raise additional capital to fund the production of medical cannabis and expand into markets beyond the UK – beginning with Germany and Poland later this year. It is also planning to launch a “premium CBD lifestyle brand”.

Read more: Through the smoke: The legal path to Britain’s cannabis market

Commenting on the raise, Cannaray chief executive officer Scott Maguire said the firm wants to become “not only the leading European cannabis player but eventually one of the global leaders in research and development of improved cannabis therapies”.

“Cannaray’s brand mission is to become a socially conscious cannabis company while simultaneously working to professionalise the industry with products that offer tangible benefits,” he added.

Read more

Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma

Share this article

  • Facebook
  • X
  • LinkedIn
  • WhatsApp
  • Email

Similarly tagged content:

Sections

  • News

Categories

  • Morning Wire Content

Trending Articles

  • Andy Burnham hints at tax rises in Autumn Budget

  • Can debt-ridden Morrisons become a Big Four supermarket again?

  • As it happened: Stocks rally; US to unveil ‘economic D-Day’ Iran sanctions

  • Budget 2026: Which taxes will Burnham and Healey hike?

  • Poundland loss doubles as discount retailer nears sale

More from Morning Wire

  • Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma

    Business Wire
  • Organigram Reports Record Third Quarter Fiscal 2026 Results

    Business Wire
  • Banning vape shops won’t fix scuzzy high streets

    Opinion
    High street vape shop Ecigwizard next to Costa Coffee and Subway, with people walking and sitting outside.
  • Exclusive: Blackstone set to back AI ‘droid’ firm at $3.5bn valuation

    AI
    Blackstone skyscraper with modern architecture under clear blue sky, symbolizing financial power and urban development.
  • Legora eyes $10bn funding valuation four months after last raise

    AI
    Canada skyline
  • Azalea Vision Appoints Co-Founder Andrés Vasquez Quintero as Chief Executive Officer to Lead Next Phase of Clinical Development

    Business Wire
  • Doctors union tops up £1m reserve pot for strikes

    Healthcare
    GettyImages 2246649047: Business professionals discussing strategy at a conference table, highlighting teamwork and collab...
  • Goldman and Intel back $5.4bn AI video startup

    Tech
    Goldman Sach bosses said that US stocks were increasingly less preferable than those in the UK and Europe.
MorningWire

Independent European business, markets and political news for decision-makers.

Morning Briefing

Europe

  • Germany
  • France
  • EU Institutions
  • Europe

Business

  • Markets
  • Business
  • Economy
  • Regulation
  • Competition
  • Public Affairs

Editorial

  • Opinion
  • Editorial Policy
  • Corrections
  • Contact

Company

  • About Morning Wire
  • Privacy Policy
  • Terms of Use
  • Cookie Policy
© 2026 Morning Wire Ltd · Published by Morning Wire Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
Privacy · Terms · Cookies · Facebook